655248-57-0

Basic information

• Product Name: 4-aMino-2-broMobenzaldehyde
• Synonyms: 4-aMino-2-broMobenzaldehyde
• CAS NO: 655248-57-0
• Molecular Formula: C₇H₆BrNO
• Molecular Weight: 200.03264
• Mol File: 655248-57-0.mol
• Article Data: 1

Chemical Properties

• Melting Point: 148 °C
• Boiling Point: 324.9±27.0 °C(Predicted)
• Appearance: /
• Density: 1.672±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 0.80±0.10(Predicted)
• CAS DataBase Reference: 4-aMino-2-broMobenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 4-aMino-2-broMobenzaldehyde(655248-57-0)
• EPA Substance Registry System: 4-aMino-2-broMobenzaldehyde(655248-57-0)

Safety Data

• Hazardous Substances Data: 655248-57-0(Hazardous Substances Data)

Usage

General Description

"4-Amino-2-bromobenzaldehyde" is a chemical compound with the molecular formula C7H6BrNO. It is a derivative of benzaldehyde, with a bromine atom and an amino group attached to the benzene ring. 4-aMino-2-broMobenzaldehyde is used in various organic synthesis reactions and as an intermediate in the production of pharmaceuticals and agrochemicals. It is also used in research and development to create new compounds for various applications. 4-Amino-2-bromobenzaldehyde must be handled with care, as it is a potentially hazardous chemical and may cause irritation to the skin, eyes, and respiratory tract.

Upstream product

• 591-19-5 m-Bromoaniline 
• 7745-93-9 2-bromo-4-nitrotoluene 

Relevant articles and documents

4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES

The present invention provides 4-anilido substituted quinazoline compounds which are potent inhibitors of protein tyrosine (PTK) kinase activity, particularly epidermal growth factor receptor (EGFR) kinase activity, and pharmaceutical compositions comprising these compounds. The present invention further provides methods of inhibiting the activity of a protein tyrosine kinase (PTK), for example an EGFR kinase, comprising the step of contacting the PTK with an effective inhibitory amount of any of the quinazoline compounds defined herein. The present invention further provides a method of inhibiting the activity of a protein tyrosine kinase (PTK) in a subject, for example an EGFR kinase, comprising the step of administering to the subject a therapeutically effective amount of any of the quinazoline compounds defined herein. The present invention further provides a method of treating or preventing a protein tyrosine kinase (PTK) related disorder in a subject, for example an EGFR related disorder, comprising the step of administering to the subject a therapeutically effective amount of any of the quinazoline compounds defined herein. The quinazoline compounds are useful in treating a variety of PTK related disorders such as cell proliferative disorders, fibrotic disorders, metabolic disorders and cancer.